A paradigm shift incellular-based therapyfor regenerative medicine
Our platform technologies Progenza™ and Sygenus are novel approaches to pain, that leverage stem cells as cellular pharmacies and utilise Secretome as a therapeutic agent.
Company update and season’s greetings from Regeneus
Regeneus CEO Karolis Rosickas shares a company update as we look ahead to 2021.
2020 Annual General Meeting – Recording
Regeneus (ASX:RGS) held its 2020 Annual General Meeting on Wednesday 14 October, 2020 at 2:30pm. For shareholders that missed it, you can listen to the recording below, and refer to the Results of Annual General Meeting ASX announcement here. …
Regeneus CEO Leo Lee with Proactive at the ASX Small and Mid-Cap Conference 2020
Regeneus CEO Leo Lee speaks to Proactive Investors' Andrew Scott while at the virtual ASX Small and Mid-Cap Conference 2020. During the interview, Leo talks about how Regeneus is working towards its mission to improve the quality of life for patients suffering from pain through their regenerative…
Mesenchymal Stem Cells: The Next Generation of Pain Treatments
Regeneus CEO Leo Lee is featured in the October 2020 edition of the European Pharmaceutical Review, writing on the field of regenerative medicine and its potential to dramatically transform the way that pain is treated. Read Leo's full article in the European Pharmaceutical Review October 2020…
Regeneus featured in Morgans ‘Under The Microscope’ podcast
Morgans analyst Iain Wilkie sat down with Regeneus CEO Leo Lee to talk about the company's recent collaboration and licensing deal for Progenza OA for knee osteoarthritis in Japan and what it means for the company. Listen to the podcast here.
The Science
MSCs and Secretome are the next frontier in targeting pain and inflammation. They combine to make a 'bioactive soup' that repurposes inflamed tissue at a site of injury, helping reduce pain and further tissue damage.
Product Pipeline
Our platform technologies Progenza™ and Sygenus represent a potential major paradigm shift in treating pain and inflammation at its source, by harnessing the power of MSCs and Secretome.
IP and Manufacturing
Our manufacturing techniques ensure cost-effective and high batch-to-batch consistency in our stem cell production. Alongside our research partners, we can scale up our platform technologies to meet market demand.
Partnering with us
Regeneus is constantly looking for partners and research collaborators.
Contact us for more information.